Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

Revenues up 4% in the quarter, driven by Humira

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie
 
2Q Revenues: $4.7 billion (+4%)

2Q Earnings: $1.1 billion (-16%)

YTD Revenues: $9.0 billion (+4%)

YTD Earnings: $2.0 billion (-5%)

Comments: Humira sales were up 12% to $2.6 billion in the quarter. Kaletra sales were $278 million, up 1%. TriCor/Trilipix sales were down 66% to $107 million due to loss of exclusivity. Niaspan sales were up 10% to $232 million. Synthroid sales were up 24% to $153 million. Zemplar sales were up 13% to $107 million, and Creon sales were up 21% to $106 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters